CClinicalTrials.gg
CompletedNCT02801019Updated Jun 15, 2016

Vitamin E-Diffused Highly Cross-Linked Polyethylene Liner

An interventional study of E-poly and ArComXL in Osteoarthritis, sponsored by Sahlgrenska University Hospital. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-06-15.

Sponsored by Sahlgrenska University Hospital · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

Vitamin E incorporated highly cross linked polyethylene (E-XLPE) was developed to increase oxidative resistance of highly cross-linked polyethylene (XLPE) without affecting mechanical properties. The investigators evaluated this type of polyethylene in a randomized clinical study, using Radiostereometric Analysis (RSA). The objective of this study was to compare the early-term wear of E-XLPE to a compression annealed polyethylene liner (C-XLPE, ArComXL®). The clinical outcome at two years was not expected to be affected by the choice of polyethylene.

Read the detailed description

First generation of modern highly cross-linked polyethylene (XLPE) was clinically introduced in 1998 and has in most countries become standard as bearing surface in total hip arthroplasty. Studies of these materials have shown significantly reduced femoral head penetration when compared to gamma sterilized conventional polyethylene.

Thermaly treating (melting or annealing) is often a part of the manufacturing process of highly cross-linked polyethylenes. The polyethylene is exposed to irradiation to achieve cross-linking and improve wear resistance. Cross-linking by irradiation increases the amount of free radicals in the material.These radicals must be eliminated or stabilized to avoid oxidative degradation over time.Thermal treatment improves oxidation resistance but potentially changes the mechanical properties of the polyethylene.

By annealing i.e. heat treatment under the melt temperature the material maintains better mechanical properties, but elimination of free radicals is suboptimal, which can lead to oxidation in vivo.Heat treatment of the polyethylene above the melt temperature will more effectively reduce or eliminate the amount of residual free radicals. This will increase oxidation resistance, but will negatively influence the mechanical properties of the material.

Due to these limitations new generations of cross-linked polyethylene materials have been developed. Introducing Vitamin E (α-tocopherol), a natural antioxidant into the material prevents oxidative degradation and stabilizes the free radicals found in irradiated polyethylene plastic. In laboratory tests, polyethylene liners with incorporated vitamin-E have demonstrated similar wear, greater strength and better resistance to oxidation compared with the first generation cross-linked polyethylene. Currently, there are only laboratory studies on vitamin E diffused polyethylene available.

The hypothesis in this study is that the early-term E-XLPE wear is low and comparable to a heat-treated XLPE. The investigators also hypothesize that implant fixation and clinical outcome at two years will be unaffected by the choice of polyethylene.

The investigators therefore evaluated the early bedding in and wear in an uncemented arthroplasty supplied with liners made of vitamin E diffusion doped XLPE (E1®, Biomet, Warsaw, IN, USA). In the control group the investigators used the same uncemented hip prosthesis with polyethylene liners manufactured to achieve high levels of crosslinking without sacrificing the mechanical strength and extinguish residual free radicals (ArComXL® , Biomet, Warzaw, IN, USA).

02

Conditions studied

  • Osteoarthritis

Browse trials for

03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 70 is close to the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Sahlgrenska University Hospital is the lead sponsor of 259 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • primary and certain subgroups of secondary osteoarthritis
  • Patients aged 20-75 years

Exclusion criteria

Exclusion Criteria:

  • inflammatory arthritis
  • cortisone or chemotherapy treatment
  • known osteoporosis or osteomalacia
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    E-XLPE

    E-poly

    Other: E-poly · Other: ArComXL

  • Active comparator
    C-XLPE

    ArComXL

    Other: E-poly · Other: ArComXL

Interventions

  • OtherE-poly

    comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years

  • OtherArComXL

    comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years

06

What researchers measure

Primary outcomes

  1. Wear of vitamin E incorporated highly cross linked polyethylene

    Evaluation of the early bedding in and wear in an uncemented arthroplasty supplied with liners made of vitamin E diffusion doped XLPE in comparsion to annealed polyethylene liner, ArComXL.

    Time frame: up to 2 years

Secondary outcomes

  1. Cup and stem translations

    Evaluation of cup and stem translations of vitamin E incorporated highly cross linked polyethylene compared to annealed polyethylene liner ArComXL liner.

    Time frame: up to 2 years

Other outcomes

  1. Precision of the Radiostereometric analysis method

    The differences between the postoperative double-examinations was used to compute the precision for the method.

    Time frame: Postoperatively, whitin 3 to 5 days after surgery

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02801019
Lead sponsor
Sahlgrenska University Hospital
Responsible party
Bita Shareghi (PhD student, Sahlgrenska University Hospital) — Principal investigator
First posted
Jun 15, 2016
Start date
Jun 2008
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Jun 15, 2016

Study contacts

Johan Kärrholm, Professor
principal investigator · Sahlgrenska University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion